Some clinical studies and real world evaluations published in top peer reviewed journal publications are listed below.

Study 1: BMJ Open Journal, https://pubmed.ncbi.nlm.nih.gov/34667011/
Multicentric study to evaluate the effectiveness of Thermalytix as compared with standard screening modalities in subjects who show possible symptoms of suspected breast cancer. BMJ Open. 2021;11(10):e052098

Study 2: ASCO JCO Journal: https://pubmed.ncbi.nlm.nih.gov/33001739/
Observational Study to Evaluate the Clinical Efficacy of Thermalytix for Detecting Breast Cancer in Symptomatic and Asymptomatic Women’, Journal of Clinical Oncology Global Oncology (JCO GO) from American Society of Clinical Oncology (ASCO). Oct 2020;6:1472-1480

Study 3: Frontiers in AI Journal, https://www.frontiersin.org/articles/10.3389/frai.2022.1050803/full
A prospective evaluation of breast thermography enhanced by a novel machine learning technique for screening breast abnormalities in a general population of women presenting to a secondary care hospital. Frontiers in Artificial Intelligence. 2023 Jan 4;5:1050803

Study 4: International Journal Of Community Medicine And Public Health https://www.ijcmph.com/index.php/ijcmph/article/view/10481
Feasibility and outcomes of using a novel artificial intelligence enhanced breast thermography technique, Thermalytix, in screening for breast abnormalities at primary health centres at the community level in South India, International Journal Of Community Medicine And Public Health, Vol. 9 No. 12 (Dec 2022)

Study 5: Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00419-3/fulltext
Performance of artificial intelligence-based breast cancer screening in a community setting: a real-world evaluation study. The Lancet Oncology. 2022 Jul 1;23:S20

Study 6: SABCS 2022 https://aacrjournals.org/cancerres/article/83/5_Supplement/P3-03-25/717325

An Automated Risk Stratification System for Breast Cancer Screening using Thermalytix. Cancer Research. 2023 Mar 1;and San Antonio Breast Cancer Symposium Dec 2022:P3-03

Thermogram early stage breast cancer screening solution is a non-contact, non-invasive, portable, safe, automated solution that works for women of all ages. The novel AI and ML algorithms for the analysis of thermal images have resulted in eleven granted US patents and many more patent applications.

Thermography is visual analysis of thermal images, while Thermalytix uses sophisticated computer aided analysis using artificial intelligence for accurate analysis of thermal maps.

Thermography is an old technique that has been in practise by some medical professionals around the world for analyzing thermal images. It is recommended as an adjunct modality to detect early-stage breast cancer.

However, manual analysis of thermal images requires highly trained skilled professionals and often results in a higher rate of false positives. Thermogram's Thermalytix solution fixes this accuracy issue using machine intelligence and provides an automated method of quantifying thermal scans, and enabling screening for early-stage breast cancer and other breast abnormalities. Thermalytix has much higher accuracy than Thermography. There are some important considerations showing why the Thermogram solution is not the same as Thermography, and those differences are detailed below:

1. Thermalytix© is different from Thermography. Though the sensing equipment used by Thermalytix is Infrared/Thermal Camera, similar to the one used by Thermographers, Thermalytix is based on analysis of temperature maps, where are thermography analyzes thermal images.

2. Thermalytix Solution uses a unique AI-enabled software that gives objective assessment of the thermal analysis, which is missing in thermography. Additionally, demography data about the patient as well as a novel vascularity analysis is performed. So, we should treat Thermalytix as a new solution for detecting breast abnormalities.

3. Thermography clinics provide a report based on visual analysis of thermal images. Thermal images are very complex with about 400,000 temperature points shown as a color pixel, where each pixel can be any of the 2000 colors. Analyzing and interpreting these thermal images with just visual inspection is a huge cognitive overload for even an experienced thermographer. So, the manual diagnosis used in Thermography is error prone and hence the FDA guidance of using thermography as an adjunct to existing methodologies. However, Thermalytix is not Thermography.

4. Thermography clinics are also NOT able to provide any report with one sitting of the patient. They usually ask the patient to come back in 3 months and do a visual inspection of 2 different sets of images taken 3 months apart. This results in potentially missing a case that was evident in the first sitting and delaying the identification of malignancy for the patient. NIRAMAI solution is able to analyse the thermal images for every screening instance and provide a quantitative report.

5. Thermalytix solution is based on machine learning models – that have the ability to analyse all the 400,000 color points both in imaging domain as well as temperature domain. A difference of 0.02 deg C is perceived by NIRAMAI software and hence the analysis is very sensitive, unlike thermography where two different shades of a color are hard to distinguish.

6. Thermalytix machine learning models are calibrated with historical data labelled with current standard of care. The way Thermalytix models were trained was based on labels learnt from mammography + sono-mammography + biopsy. It was not trained using reports of thermographers, hence Thermalytix results are more accurate and better than current standard of care.

7. Thermalytix additionally uses patented vascular biomarkers which is able to detect very deep tumours, which are generally missed by thermographers, as there may not be an increase in temperature for the same.

8. In order to make an objective comparison between Thermography and Thermalytix, a clinical trial on 303 patients was conducted in a blinded retrospective analysis. This was peer-reviewed and published in International Conference on Advances in Breast Cancer Treatments, Kyoto, Japan, April 26-27, 2018. The results of this comparison showed a remarkable improvement in performance of Thermalytix over Thermography. An increase of 70% was seen in Positive Predictive Value over Thermography was seen, with very high levels of sensitivity and specificity.